Anika Therapeutics, Inc. 10-Q

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS   Issuer Purchases of Equity Securities   Under our equity compensation plans, and subject to the approval of the Compensation Committee of our Board of Directors, employee grantees have the option of electing to satisfy tax withholding obligations at the time of vesting or exercise by allowing us to withhold shares of stock otherwise issuable to the grantee. During the three-month period ended June 30, 2021, we withheld 1,093 shares to satisfy grantee tax withholding obligations on restricted stock award and restricted stock unit vesting events.   Following is a summary of stock repurchases for the three-month period ended June 30, 2021 (in thousands, except share data):   Period   Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (1)     Average Price per Share     Maximum Number (or Approximate Dollar Value) of Shares that May Yet be Purchased Under the Plans or Programs(2)   April 1 to 30, 2021     -     $ -     $ 20,000   May 1 to 31, 2021     637     $ 43.72     $ 20,000   June 1 to 30, 2021     456     $ 43.50     $ 20,000   Total     1,093                     (1) 1,093 shares were withheld by us to satisfy grantee tax withholding obligations on restricted stock award and restricted stock unit vesting events in May 2021. (2) On May 2, 2019, we announced that our Board of Directors approved a $50.0 million share repurchase program with $30.0 million to be utilized for an accelerated share repurchase program, which was completed in January 2020, and $20.0 million reserved for open market repurchases. No open market repurchases were made during the three-month period ended June 30, 2020.     26     ITEM 6. EXHIBITS   Exhibit   No.           †10.1 Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan (as amended effective June 16, 2021) (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K filed on June 22, 2021)       †10.2 Anika Therapeutics, Inc. 2021 Employee Stock Purchase Plan (adopted June 16, 2021) (incorporated by reference to Exhibit 99.2 to the Current Report on Form 8-K filed on June 22, 2021)       (31) Rule 13a-14(a)/15d-14(a) Certifications       *31.1 Certification of Dr. Cheryl R. Blanchard, pursuant to Rules 13a-15(e) and 15d-15(e), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.       *31.2 Certification of Michael Levitz, pursuant to Rules 13a-15(e) and 15d-15(e), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.       (32) Section 1350 Certifications       **32.1 Certification of Dr. Cheryl R. Blanchard, and Michael Levitz, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.       (101) XBRL       *101 The following materials from Anika Therapeutics, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 as filed with the SEC on August 5, 2021, formatted in Inline XBRL (eXtensible Business Reporting Language), as follows:         i. Consolidated Balance Sheets as of June 30, 2021 (unaudited) and December 31, 2020 (unaudited)   ii. Consolidated Statements of Operations and Comprehensive Income for the Three and Six Months Ended June 30, 2021 and June 30, 2020 (unaudited)   iii. Consolidated Statements of Stockholders’ Equity for the Six Months Ended June 30, 2021 and June 30, 2020 (unaudited)   iv. Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2021 and June 30, 2020 (unaudited)   v. Notes to Consolidated Financial Statements (unaudited)     104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)      * Filed herewith. ** Furnished herewith. †    Management contract or compensatory plan or arrangement.     27     SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.       ANIKA THERAPEUTICS, INC.         Date: August 5, 2021 By: /s/ MICHAEL LEVITZ       Michael Levitz       Executive Vice President, Chief Financial Officer and Treasurer     (Authorized Officer and Principal Financial Officer)                                           28